Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiome Disruptions During and After Antimicrobials
NCT03098485Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2017
- Primary completion
- Aug 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of levofloxacin, azithromycin and cefpodoxime in community acquired pneumonia (CAP) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 days, Degree of Microbial Disruption: Number of Patients With Increase in Antibiotic Resistance Genes at 185 days and 1 more. Started Jan 2017; status: completed.
02
Drugs
levofloxacinazithromycincefpodoxime
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03098485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098485.